Back to List View Graph View

Acyl-CoA synthetase long-chain family member 4 (ACSL4)

Acyl-CoA synthetase long chain family member 4 (ACSL4) is a long-chain acyl-CoA synthetase that has emerged as an important regulator of lipid metabolism and ferroptosis.

Where the papers sit

10 papers from the last 6 months study Acyl-CoA synthetase long-chain family member 4 (ACSL4) directly · updated from PubMed 10 Nov 2026

Study type 0 clinical trials · 1 human data · 7 preclinical · 2 unclassified

Themes 3 themes

  • Ferroptosis Across Diseases

    Ferroptosis is being treated as a disease-modifiable process, with suppression favored in neurodegeneration, microvascular injury, and bone loss but induction explored against pancreatic cancer. Brain-targeted dual-function PROTACs and Parkin-mediated ACSL4 ubiquitination aim to reduce lipid peroxidation and restore tissue function. Nrf2-dependent protection and Schisandrin B likewise show context-specific control of ferroptotic stress. The central open question is how to inhibit neuronal and vascular damage without weakening ferroptosis-based tumour killing.

    4 papers · 40%

  • Ferroptosis in Tissue Injury

    Ferroptosis is being linked to ischemic, toxic, and neurodegenerative injury through iron, reactive oxygen species, lipid peroxidation, and glutathione loss. Work on myocardial ischemia-reperfusion and cisplatin-induced acute kidney injury points toward antioxidant and ferroptosis-blocking interventions, including multifunctional polydopamine nanoparticles. Early-onset Alzheimer’s disease studies add computationally nominated ferroptosis genes and druggability rather than a validated therapy. The field is moving from association toward experimental validation, but tissue-specific targets and clinical benefit remain unresolved.

    3 papers · 30%

  • Lipid Metabolism in Cancer

    Lipid metabolic reprogramming is emerging as a route to lymphatic metastasis and targeted-therapy resistance in cancer. Dual ACSL3/4 inhibition is being used to reshape metabolic and immune microenvironments, while triacsin C-based lipid remodeling is explored to overcome MEK inhibitor resistance. ZDHHC9-driven palmitoylation of ACSL3 links lipid metabolism to cetuximab resistance in colorectal cancer. The recurring direction is toward disrupting ACSL-dependent lipid supply and modification, although the relative roles of ACSL3 and ACSL4 remain context-dependent.

    3 papers · 30%

Papers

The 10 papers from the last 6 months that study Acyl-CoA synthetase long-chain family member 4 (ACSL4) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Ferroptosis Across Diseases (4)
  1. Dual-function PROTAC suppresses ferroptosis and restores neuronal function via brain-targeted delivery. Cell chemical biology · 21 Jul 2026 PMID 42480533
  2. Ubiquitination of ACSL4 by Parkin Suppresses Ferroptosis and Rescues Glucocorticoid-Induced Bone Loss. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 13 Jul 2026 PMID 42439361
  3. Schisandrin B exhibits anti‑proliferative effects by inducing ferroptosis in pancreatic cancer. Oncology reports · 19 Jun 2026 PMID 42318966
  4. Nuclear Factor Erythroid 2-Related Factor 2-Dependent Ferroptosis Suppression by Salvianolic Acid B Preserves Microvascular Integrity and Reduces Risk Factors for Hemorrhagic Transformation After Cerebral Infarction. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 26 May 2026 PMID 42186809
Ferroptosis in Tissue Injury (3)
  1. Integrated bioinformatics analysis, machine learning, and experimental validation reveal that ACSL1 drives myocardial ischemia reperfusion injury via ferroptosis. Journal of bioenergetics and biomembranes · 24 Sept 2026 PMID 42782425
  2. Neural network-enhanced investigation of ferroptosis and druggability in early-onset alzheimer's disease. Metabolic brain disease · 20 Jul 2026 PMID 42474555
  3. Multifunctional Polydopamine Nanoparticles to Alleviate Oxidative Stress and Inhibit Ferroptosis for Cisplatin-Induced Acute Kidney Injury Therapy. Molecular pharmaceutics · 11 Jul 2026 PMID 42435348
Lipid Metabolism in Cancer (3)
  1. A lymph node-targeted nanoplatform reprograms metabolic and immune microenvironments via dual ACSL3/4 inhibition in lymphatic metastatic tumors. Journal of controlled release : official journal of the Controlled Release Society · 1 Oct 2026 PMID 42822540
  2. ZDHHC9 regulates lipid metabolic reprogramming by mediating palmitoylation of ACSL3 to promote cetuximab resistance in colorectal cancer. Experimental cell research · 25 Sept 2026 PMID 42790666
  3. A pH-responsive silver nanoparticle platform overcomes MEK inhibitor resistance in neurofibroma via triacsin C-mediated lipid metabolic reprogramming. Apoptosis : an international journal on programmed cell death · 24 May 2026 PMID 42177691

By study type

Human data, design not indexed (1)
  1. Neural network-enhanced investigation of ferroptosis and druggability in early-onset alzheimer's disease. Metabolic brain disease · 20 Jul 2026 PMID 42474555
Preclinical: animal, cell and lab studies (7)
  1. A lymph node-targeted nanoplatform reprograms metabolic and immune microenvironments via dual ACSL3/4 inhibition in lymphatic metastatic tumors. Journal of controlled release : official journal of the Controlled Release Society · 1 Oct 2026 PMID 42822540
  2. ZDHHC9 regulates lipid metabolic reprogramming by mediating palmitoylation of ACSL3 to promote cetuximab resistance in colorectal cancer. Experimental cell research · 25 Sept 2026 PMID 42790666
  3. Integrated bioinformatics analysis, machine learning, and experimental validation reveal that ACSL1 drives myocardial ischemia reperfusion injury via ferroptosis. Journal of bioenergetics and biomembranes · 24 Sept 2026 PMID 42782425
  4. Multifunctional Polydopamine Nanoparticles to Alleviate Oxidative Stress and Inhibit Ferroptosis for Cisplatin-Induced Acute Kidney Injury Therapy. Molecular pharmaceutics · 11 Jul 2026 PMID 42435348
  5. Schisandrin B exhibits anti‑proliferative effects by inducing ferroptosis in pancreatic cancer. Oncology reports · 19 Jun 2026 PMID 42318966
  6. Nuclear Factor Erythroid 2-Related Factor 2-Dependent Ferroptosis Suppression by Salvianolic Acid B Preserves Microvascular Integrity and Reduces Risk Factors for Hemorrhagic Transformation After Cerebral Infarction. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 26 May 2026 PMID 42186809
  7. A pH-responsive silver nanoparticle platform overcomes MEK inhibitor resistance in neurofibroma via triacsin C-mediated lipid metabolic reprogramming. Apoptosis : an international journal on programmed cell death · 24 May 2026 PMID 42177691
Unclassified: not yet indexed with MeSH (2)
  1. Dual-function PROTAC suppresses ferroptosis and restores neuronal function via brain-targeted delivery. Cell chemical biology · 21 Jul 2026 PMID 42480533
  2. Ubiquitination of ACSL4 by Parkin Suppresses Ferroptosis and Rescues Glucocorticoid-Induced Bone Loss. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 13 Jul 2026 PMID 42439361